Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $43.75, along with a high estimate of $53.00 and a low estimate of $37.00. A decline of ...
Two new products will be introduced: A new version of its EVOLUX extended monofocal intraocular lens (IOL) with an improved injection technology ... and five e-Posters will feature clinical outcomes ...
Custom Lens Replacement surgery is a transformative procedure that replaces the eye’s natural lens with an artificial intraocular lens (IOL), effectively correcting vision issues such as myopia ...
Zaltenibart is under clinical development by Omeros and currently in Phase II for Glomerulonephritis. According to GlobalData, Phase II drugs for Glomerulonephritis have a 35% phase transition success ...